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Abstract 
Objectives: Ecological momentary sampling in BD research requires brief symptom measures with low cognitive 
demands to maximize data collection across the range of BD symptomatology. We developed the BD Sx cognizant of 
the challenges inherent in scale development with low prevalence populations and the limitations of existing meas‑
ures (e.g., over‑reliance on patients in acute states recruited from psychiatric settings). In order to be generalizable 
across the full spectrum of the illness, we also included those currently euthymic and those who avoid clinical contact.
Methods: We recruited a global sample of 1010 adults with BD over 19 days using socio‑demographically targeted, 
social media advertising and online data collection. At follow‑up, 428 participants provided responses 67 days later on 
average. This enabled us to develop the BD Sx and replicate initial findings across multiple samples over time.
Results: Both exploratory and confirmatory factor analyses support a 4‑factor BD Sx model. Goodness of fit indices 
indicate good model fit across samples and over time. We labeled these factors: elation/loss of insight, affrontive 
symptoms of mania, cognitive/depressive, and somatic/depressive symptoms. Affrontive symptoms correlate posi‑
tively with cognitive and somatic depression factors, which may suggest mixed‑state symptom clusters in accord with 
DSM 5.
Conclusions: Responses to the BD Sx reliably measure both depressive and hypo/manic symptoms. Temporal 
invariance analyses indicate that the 4‑factor structure is consistent over time. Future research  should compare BD Sx 
responses to clinical diagnoses of hypo/mania and major depressive episodes.
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Background
Bipolar disorder (BD) is a chronic mental health condi-
tion defined by extremes of mood and mood variability 
(DSM-5 American Psychiatric Association 2013). Change 
in BD symptomatology can occur over the course of 
days, hours, and even minutes. As of yet, however, few 
if any self-report instruments exist to gauge change in 
symptom levels over short intervals. Existing scales were 
developed with non-clinical populations to measure 
normal mood, not symptomology [e.g., Profile of Mood 
States, POMS (Heuchert and McNair 2012); Positive and 
Negative Affect Scale, PANAS (Watson et al. 1998)].
A fundamental challenge in scale development with 
low prevalence populations such as BD is recruitment 
of samples of sufficient size given that psychometric 
research generally requires 200–300 participants (Clark 
and Watson 1995). As noted by Floyd and Widaman 
(1995), factor analysis conducted with small samples 
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produces invalid or unstable factor structures unlikely 
to be replicated with other samples or generalize to the 
population. Moreover, scale development with clinical 
populations commonly relies on refractory patients or 
those in acute states in psychiatric settings (e.g., Michalak 
and Murray 2010). Yet research indicates that such sam-
ples are not representative of their respective populations 
(Dura and Kiecolt-Glaser 1990; Gallagher et  al. 1989; 
Haberfellner 2000; Stirman et  al. 2005). In other words, 
inpatient and outpatient BD samples commonly exclude 
those coping effectively, those supported by general prac-
titioners in the community, and those who avoid clinical 
contact. However, valid and reliable test construction 
requires large samples recruited across multiple sites and 
settings (ideally multiple countries), reflecting the full 
range of BD symptomatology, including those who are 
currently euthymic. We developed the BD Sx cognizant 
of these challenges and the psychometric limitations of 
existing scales.
Bipolar affective and older adults (BADAS) study
For our BADAS Study, we developed and validated BD 
Sx to enable ecological momentary sampling [EMS 
(Wenze and Miller 2010)] of hypo/manic and depres-
sive symptoms using the iOS app we developed for iPad 
and iPhone (King et  al. 2016). It is essential that EMS 
measurement be rapid and reliable with low cognitive 
load (Choi and Lee 2012). In order to minimize missing 
data, EMS questionnaires must be brief with low cog-
nitive demands. This is especially true for BD research 
when participants are acutely symptomatic. For the BD 
Sx, we adopted the format used for frequent measure-
ment of mood and mood variability developed with non-
clinical populations [e.g., POMS (Heuchert and McNair 
2012), PANAS (Watson et al. 1998)]. In other words, we 
compiled a set of mood adjectives measuring both hypo/
manic and depressive symptoms, asking respondents to 




For the BADAS Study, we recruited 1010 adults with BD 
mostly from Canada, the US, UK, Ireland, South Africa, 
Australia, and New Zealand. This was achieved over 
19  days using social media advertising targeted directly 
to those with BD. Participants were drawn from a global 
population of approximately 6.2 million English-speak-
ing, adult Facebook users with ‘bipolar disorder interests’ 
(e.g., members of online BD support networks). Half the 
sample was 45+ years of age by design. As a response 
incentive, one randomly selected participant received 
a $500 lottery prize. The BADAS study was undertaken 
with full ethics approval from the Research Ethics Board 
at Simon Fraser University (2014s0375).
By clicking on advertisements appearing along the 
sidebar, or embedded within newsfeeds, prospective par-
ticipants were directed to an online consent form that 
specified study inclusion criteria. Thereafter they com-
pleted a series of counterbalanced online questionnaires 
hosted on a secure university https server; responses 
were encrypted before transmission. The majority of par-
ticipants provided an email address and consent to re-
contact, allowing us to collect Time 2 responses 2 months 
later.
To corroborate that participants were in fact persons 
with BD, they were asked to specify their diagnosis (and 
BD subtype), date of birth, and country of residence at 
both points of measurement; rates of concurrence were 
97, 96, and 97  %, respectively. In addition, participants 
were asked to list any prescribed psychotropic medica-
tions by category and comorbid conditions. Of those 
specifying medications, 95  % correctly listed and cat-
egorized both mood stabilizers and antidepressants, and 
84  % for antipsychotics. Also, comorbid conditions and 
the relative frequency reported by participants corre-
spond to epidemiological BD research [i.e., anxiety disor-
ders most commonly cited (Lala and Sajatovic 2012)].
In light of participants’ ability to specify their pre-
scribed medications with such accuracy (and concur-
rence between T1 and T2 responses to date of birth and 
country of residence questions), we contend it is very 
unlikely that participants invented or mispecified their 
BD diagnosis. And even if several concocted their identi-
ties, participating only to be included in the lottery,  our 
sample size was sufficiently large so that their responses 
would have had little or no impact on our findings (i.e., 
minimal measurement error). In no small degree, this 
is due to the fact that social media advertisements were 
directed specifically to prospective participants with BD 
and not other populations. This methodology has been 
used with a range of clinical and other circumscribed 
populations which we describe in detail elsewhere (King 
et al. 2014).
Participant descriptive features
This sample was composed of 736 women, 266 men, and 
6 specifying another gender (e.g., transgender). They 
ranged in age from 19 to 82  years, (mean) M  =  45.28, 
(standard deviation) SD = 13.78. The largest proportion 
of participants lived in the U.S. (40 %) with 29 % in Can-
ada, 17  % from the U.K., and 6  % from Ireland; smaller 
numbers living in Australia, New Zealand, and South 
Africa in descending order. In total, participants from 
23 countries provided baseline responses; 90 % reported 
that they were Caucasian. Thirty per cent indicated that 
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they were married whereas an almost equal number were 
currently single (28  %). A further 20  % were partnered 
(e.g., civil union) and 18  % separated or divorced. Only 
2 % were widowed.
Of those reporting their specific diagnosis, roughly 
equal numbers indicated that they had been diagnosed 
with BD not otherwise specified (NOS 35 %) and BD II 
(34 %) whereas 27 % reported a BD I diagnosis. Eighteen 
per cent were unsure or unaware of their BD subtype. 
On average, participants had been diagnosed with BD 
11.14  years ago (SD  =  9.60, range 1  month–51  years), 
had 1.11 comorbid psychiatric conditions (SD  =  1.38, 
range 0–6), and reported 2.47 prescribed medica-
tions (SD = 1.77, range 0–15). Most listed one or more 
mood stabilizer (58.9 %) and 1+ antidepressant (64.4 %) 
whereas smaller numbers listed 1+ anxiolytic (38.9  %) 
and 1  +  antipsychotic (38.3  %). These percentages are 
commensurate with the BD subtypes reported by partici-
pants. By category, lithium (n = 78), bupropion (n = 43), 
clonazepam (n = 55), and quetiapine (n = 68) were the 
medications most commonly listed by participants 
(mood stabilizer, antidepressant, anxiolytic and antipsy-
chotic, respectively). In their qualitative comments, sev-
eral participants reported that they have discontinued 
pharmacotherapy (or now self-medicate with marijuana).
Although participants reported that they had com-
pleted 11.40  years of education on average (SD  =  5.90, 
range 1–25), 21  % indicated that they were currently on 
sick leave or receiving a disability pension and 16 % were 
unemployed. Just 14  % were employed full-time, 13  % 
worked part-time, and 6 % were retired. Of those currently 
or previously employed, 25 % indicated that they worked 
in managerial/clerical position, 19  % were employed in 
professional/technical positions, 11 % in semi-skilled, and 
10  % in skilled trades (e.g., electricians); the largest per-
centage (34 %) reported no paid work history. Consistent 
with previously published research (e.g., Hooshmand et al. 
2014), these participants were largely under-employed rel-
ative to their education and qualifications.
Instruments
Patient Health Questionnaire (PHQ-9) The PHQ-9 
(Kroenke and Spitzer 2002) is a self-report version of 
the depression module from the PRIME-MD diagnostic 
interview (Spitzer et  al. 1995). Participants respond to 
each of 10 PHQ-9 items (4 response options) based on 
problems they have experienced over the past 2  weeks. 
A total greater than 9 suggests significant symptomology 
with 89 % sensitivity and 88 % specificity vis-à-vis a diag-
nosis of a major depressive episode (Kroenke et al. 2001). 
The PHQ-9 has been used widely with unipolar and bipo-
lar patient populations (Cerimele et al. 2014).
Satisfaction with Life Scale (SLS) The SLS (Diener et al. 
1985) serves to measure perceived quality of life on the 
basis of person-specific criteria. Respondents compare 
their current circumstances against subjective standards 
to arrive at a global appraisal of life satisfaction (Diener 
2000). Participants are presented with five separate ques-
tions with seven response alternatives (e.g., “In most 
ways my life is close to ideal”; “The conditions of my life 
are excellent”). Previously published research indicates 
that depression is associated with lower life satisfaction, 
whereas SLS is unrelated to hypo/manic symptoms of 
bipolar disorder (Meyer et al. 2004).
Analytic strategy
Our 1010 participants were randomly assigned to one 
of three groups: 300 for initial exploratory factor analy-
ses (EFA); 300 to a second EFA sample to replicate ini-
tial findings; and the remaining 411 participants were 
assigned to confirmatory factor analyses (CFA) to assess 
the measurement properties of the working version of 
the BD Sx derived on the basis of EFA findings. Partici-
pants responded to an initial pool of mood and symptom 
adjectives as well as the PHQ-9 and SLS. This was done 
in order to assess the concurrent and discriminant valid-
ity of BD Sx responses relative to established depression 
and satisfaction with life measures.
Sixty-seven days on average after initial recruitment, 
428 participants again responded to the BD Sx along with 
other measures. We set out to replicate initial CFA find-
ings; we then computed invariance analyses comparing 
T1 and T2 CFA models to assess the stability of BD Sx 
responses over time. This is a more appropriate psycho-
metric procedure than computing test–retest reliability, 
as variability in mood is the hallmark of BD. Strong test–
retest reliability would, in fact, indicate insensitivity to 
change over time. Temporal invariance analyses compare 
the underlying structure of scale responses irrespective 
of change in response levels. CFA models and invariance 
analyses were computed in accord with the procedures 
described by Byrne (2012).
Results
Study one
Exploratory Factor Analyses (EFA) We compiled a pool 
of 114 mood and symptom adjectives from existing 
scales, clinician input, and recommendations from our 
community advisory board. We then performed EFA 
with the first sub-sample of 300 participants. In accord 
with prior psychometric research with clinical popula-
tions (e.g.,  Chou and O’Rourke 2012), the likelihood 
method of factor extraction with varimax rotation was 
used. This initial pool of items demonstrated sufficient 
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interrelatedness to undertake factor analysis according 
to the Kaiser–Meyer–Olkin (KMO) measure of sampling 
adequacy (KMO = .93).
The Kaiser-Guttman criterion initially suggested a 
6-factor solution (i.e., eigenvalues  >1); however, the 
Cattell-Nelson-Gorsuch (CNG) scree test indicated a 
4-factor solution due to the notable leveling of eigenval-
ues after Factor 4. This 4-factor solution explained 49 % 
of observed variance. [As noted by Floyd and Widaman 
(1995), the Kaiser-Guttman criterion generally provides 
over-inclusive factor solutions.] Coefficient values for 
each of the top 10 items loaded on their respective fac-
tors with coefficient values greater than .30 as recom-
mended (Tabachnick and Fidell 2013), most greater 
than .60.
EFA was next performed on a second subset of 300 
participants with results very similar to the first EFA. A 
4-factor solution was again most viable with the same 
items emerging as best measures of their respective fac-
tors, and in virtually the same sequence. Where two items 
had similar meaning, we selected the adjective suggesting 
symptomatology versus normal affect (e.g., hopelessness 
vs. sadness; hostile vs. angry; euphoric vs. happy). We 
provisionally selected 20 adjectives to measure these four 
BD Sx factors. Based on the meaning conveyed by each 
grouping, we labeled these factors: (1) cognitive/depres-
sive; (2) somatic/depressive; (3) elation/loss of insight; 
and (4) affrontive symptoms of mania.
Confirmatory Factor analysis (CFA) We next per-
formed CFA to assess goodness of fit of this 4-factor 
model (n  =  411). Each of the 20 items loaded signifi-
cantly upon its respective factor (i.e., t values >1.96). Sig-
nificant covariance was observed between the cognitive/
depressive and somatic/depressive factors as well as the 
two hypo/mania factors (elation/loss of insight, affron-
tive symptoms). Also of note was significant covariance 
between the affrontive symptoms of mania and both cog-
nitive and somatic depression factors suggesting clusters 
of mixed-state hypo/manic and depressive symptoms 
consistent with DSM 5 (2013). See Fig. 1.
Model fit was calculated subsequent to correcting for 
correlated error between 16 of 210 possible item pairs, 
χ2(df  =  150)  =  271.30, p  <  .01. Statistical power for 
this model was .99 (O’Rourke and Hatcher 2013). The 
Comparative Fit Index (CFI ≥  .95; CFI =  .97), the Root 
Mean Square Error of Approximation (RMSEA  ≤  .05; 
RMSEA = .045), and the full 90 % confidence interval for 
the RMSEA were each within ideal limits for this model 
[.036 < RMSEA CL90 < .053; see (Hu and Bentler 1999)]. 
The Standardized Root Mean Square Residual was in 
acceptable limits (SRMR  ≤  .08; SRMR  =  .070). These 
results provide further support for the psychometric 
properties of the 4-factor model of BD Sx responses.
Construct validity The two BD Sx depression factors 
were strongly correlated (r =  .55, p <  .01) while the two 
hypo/mania factors were moderately correlated (r = .27, 
p < .01). We next computed correlation coefficients com-
paring responses to these four BD Sx factors with depres-
sive symptoms and life satisfaction. As expected, both 
cognitive/depressive and somatic/depressive factors were 
strongly correlated with responses to the PHQ-9, r = .71, 
p < .01; r = .49, p < .01, respectively. Affrontive symptoms 
of mania were also correlated with participants’ responses 
to the PHQ-9 (r =  .50, p  <  .01) whereas no association 
emerged for the elation/loss of insight factor, r = −.03, 
p = .38). These findings are consistent with CFA analyses 
showing significant covariance between affrontive symp-
toms of mania and both cognitive and somatic symptoms 
of depression, and no covariance between elation/loss of 
insight and either depression factor.
Responses to both the cognitive/depressive and 
somatic/depressive factors were significantly and 
inversely correlated with life satisfaction, r  =  −.42, 
p < .01; r = −.24, p < .01, respectively. Affrontive symp-
toms of hypo/mania were also negatively correlated with 
SLS, r = −.30, p  <  .01 whereas virtually no association 
was found between elation/loss of insight and life satis-
faction, r = −.10, p = .05. These analyses provide support 
for the concurrent validity (cf. PHQ-9) and discriminant 
validity of responses to the BD Sx (cf. SLS). Both depres-
sion factors were strongly correlated with the PHQ-9 as 
well as the affrontive mania factor (but not the elation/
loss of insight factor). Similarly, cognitive and somatic 
depression factors as well as affrontive symptoms of 
hypo/mania were inversely associated with life satis-
faction. Consistent with previous research (e.g.,  Meyer 
et  al. 2004), elation/loss of insight was unrelated to life 
satisfaction.
Study two
Of those providing Time 1 data, 97  % (or 917 of 1011) 
provided us with an email address and permission to con-
tact them in future. And 47 % (or 428 of 917) responded 
to our request for Time 2 responses roughly 2-months 
after initial data collection. This rate of retention is high 
for questionnaire research (DeVellis 2012).
An equal proportion of men and women responded 
at both T1 and T2 versus T1 only, χ2(df  =  2)  =  .09, 
p  =  .96. The ethnic composition of groups was simi-
lar [χ2(df  =  8)  =  9.50, p  =  .30]; they were roughly the 
same age [M =  45.28  years, range 19–82; t(995) =  .97, 
p  =  .33] and the relationship status of participants in 
both groups was comparable, χ2(df =  7) =  .09, p =  .13. 
Moreover, those who responded at both points of 
measurement reported the same numbers of comor-
bid conditions, t(1008)  =  .73, p  =  .50 and medication 
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adherence, t(341) = .64, p = .52. Yet those providing only 
T1 responses were less educated (n = 11.02 years) than 
those providing both T1 and T2 responses [n  =  12.15; 
t(1001) = 2.88, p < .01] and were of lower socioeconomic 
status based on work performed now or prior to retire-
ment χ2(df = 6) = 16.78, p = .01. Yet those lost to follow 
up were largely indistinguishable from the full T1 sample. 
In other words, attrition between points of data collec-
tion does not appear to be a confounding factor.
We computed a second CFA to assess the 4-fac-
tor BD Sx model, and once again, each item contrib-
uted significantly to measurement of its respective 
factor (i.e., t values  >1.96). Statistical power for this 
CFA model was again calculated as .99 (O’Rourke and 
Hatcher 2013). Goodness of fit indices were within 
acceptable to ideal parameters, χ2(df = 160) = 237.91, 
p  <  .01. More precisely, the CFI  =  .97, the 
RMSEA  =  .042, and the full 90  % confidence inter-
val for the RMSEA was within ideal parameters 
(.030 < RMSEA CL90 <  .053); the SRMR (.066) was in 
acceptable limits. These results replicate initial CFA 
findings and provide further confirmation of psycho-
metric soundness of the BD Sx.
Temporal Analyses. Invariance analyses were next per-
formed to test the temporal stability of the 4-factor model 
and the measurement reliability of BD Sx items over time. 
CFA models, initially run separately, were next computed 
simultaneously. Covariance estimates and path coef-
ficients for this 4-factor BD Sx model were anchored in 
sequence to ascertain if and where significant differences 




































Fig. 1 BD Sx 4‑Factor Model of Symptomatology in Bipolar Disorder. Parameters expressed as maximum likelihood estimates (standardized solu‑
tion). Parenthetical numbers indicate significance levels for parameter estimates (statistically significant t values >1.96)
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might exist between T1 and T2 CFA models (i.e., signifi-
cant change in the chi-square statistic). See Table 1.
Covariance between the four BD Sx factors did not dif-
fer between points of measurement supporting the fac-
torial validity of the latent structure of BD Sx responses 
over time. Also of note, the relative strength of associa-
tion between items and their respective factors differed 
for 2 of 20 items (i.e., hostile, impulsive) yet these differ-
ences are negated by overall measurement consistency of 
these items’ respective factors. In other words, responses 
to these BD Sx items are highly reliable and temporal 
analyses demonstrate considerable consistency of meas-
urement over time.
Time 2 data allowed us to replicate the 4-factor model; 
moreover, this factor structure appears valid and items 
appear reliable over time. These findings provide further 
confirmation of the psychometric properties of responses 
to this scale. We present the BD Sx in Table  2 for use 
in EMS research and other studies that require rapid, 
valid and reliable measurement of both hypo/manic and 
depressive symptoms. The BD Sx can also be used in 
clinical practice to assess change over the course of treat-
ment, and in randomized controlled studies when BD 
symptoms are measured repeatedly.
Discussion
The results of this study provide considerable psycho-
metric support for the reliability and validity of responses 
to the BD Sx. A working version of this scale was first 
developed on the basis of separate EFA analyses later 
supported by CFA, each using large samples. At follow-
up, we replicated this 4-factor model and demonstrated 
Table 1 Summary specifications and temporal invariance analyses comparing Time 1 and Time 2 BD Sx responses
* p < .05; ** p < .01
df degrees of freedom, SRMR Standardized Root Mean Square Residual, CFI Comparative Fit Index; RMSEA Root Mean Square Error of Approximation, RMSEA CL90 90 % 
Confidence Limits for the RMSEA statistic
Model χ2 df Δχ2 Δdf SRMR CFI RMSEA (CL90)
Baseline model 518.35 307 – – .0701 .97 .030 (.026–.035)
Cognitive–somatic 518.40 308 .05 1 .0699 .97 .030 (.026–.035)
Affront–elation/insight 518.43 309 .03 1 .0700 .97 .030 (.026–.035)
Affront–cognitive 518.84 310 .39 1 .0696 .97 .030 (.026–.035)
Affront–somatic 518.84 311 .05 1 .0697 .97 .030 (.026–.034)
Cognitive/depressive 529.54 316 10.65 5 .0698 .97 .030 (.026–.035)
 miserable 522.23 312 3.34 1 .0697 .97 .030 (.026–.035)
 worthless 523.30 313 .02 1 .0697 .97 .030 (.026–.035)
 gloomy 523.20 314 .01 1 .0697 .97 .030 (.026–.034)
 hopeless 525.21 315 2.22 1 .0697 .97 .030 (.026–.034)
 insecure 529.42 316 .20 1 .0698 .97 .030 (.026–.035)
 lonely 529.54 316 .12 1 .0696 .97 .030 (.026–.035)
Somatic/depressive 530.07 319 .53 3 .0697 .97 .030 (.026–.035)
 fatigued 529.89 317 .35 1 .0696 .97 .030 (.026–.035)
 sleepy 530.01 318 .20 1 .0697 .97 .030 (.025–.034)
 exhausted 530.07 319 .06 1 .0697 .97 .030 (.025–.034)
 tired 530.07 319 .16 1 .0697 .97 .030 (.025–.034)
Elation/loss of insight 538.24 323 8.17 4 .0692 .97 .030 (.026–.035)
 impulsive 535.53 320 5.46* 1 .0692 .97 .030 (.026–.035)
 indestructible 535.54 321 .01 1 .0692 .97 .030 (.026–.035)
 talkative 535.83 322 .29 1 .0694 .97 .030 (.026–.035)
 invincible 538.24 323 2.41 1 .0691 .97 .030 (.026–.035)
 euphoric 538.24 323 .29 1 .0689 .97 .030 (.026–.035)
Affrontive Sx of mania 543.93 327 5.69 4 .0686 .97 .030 (.026–.035)
 hostile 542.81 324 4.57* 1 .0686 .97 .030 (.026–.035)
 furious 543.15 325 .34 1 .0686 .97 .030 (.026–.034)
 argumentative 543.79 326 .64 1 .0686 .97 .030 (.026–.034)
 disgusted 543.93 327 .14 1 .0686 .97 .030 (.026–.034)
 suspicious 543.93 327 .80 1 .0686 .97 .030 (.026–.034)
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strong temporal consistency across two points of meas-
urement (n  =  428). This level of methodological rigor 
distinguishes development of the BD Sx from prior scales 
developed for BD research and clinical practice.
We also compared the BD Sx to established meas-
ures of life satisfaction and depressive symptomatology. 
Responses to cognitive/depressive and somatic/depres-
sive factors, and affrontive symptoms of mania, were 
each positively and significantly correlated; elation/loss 
of insight was unrelated to either cognitive or somatic 
symptoms of depression. Similarly, the elation/loss of 
insight was uncorrelated with life satisfaction whereas 
the remaining three factors are inversely related to satis-
faction with life. These analyses demonstrate the concur-
rent and discriminant validity of responses to the BD Sx.
It might seem counterintuitive that elation/loss of 
insight is not positively correlated with life satisfaction, 
though as we note, this finding is consistent with previ-
ously published research (Meyer et al. 2004). This may be 
because life satisfaction is a cumulative, global appraisal 
of one’s life to this point (Diener 2000) in contrast to 
momentary mood at one point. Future research should 
compare BD Sx responses to hypo/mania self-report 
measures to further support the psychometric properties 
of this scale.
Of further note is the significant correlation between 
affrontive symptoms of hypo/mania and both depres-
sion factors. No such correlation exists between elation/
loss of insight and neither cognitive nor somatic depres-
sion factors, as we would anticipate. The former finding is 
consistent with evolving understanding of mixed-symp-
tom BD symptomatology (DSM-5 American Psychiatric 
Association 2013) as manic and depressive symptoms are 
not inversely associated but can present concurrently for 
many or most with BD. This is in accord with the 4-factor 
model of BD Sx responses in which depression and hypo/
mania are measured as distinct but correlated constructs.
Our findings suggest that both symptoms of depres-
sion and mania fall into two separate groupings. Con-
sistent with unipolar depression research (Carney and 
Freedland 2012), depressive symptoms appear to clus-
ter in distinct somatic and cognitive groupings. Maybe 
more noteworthy is the composition of hypo/mania fac-
tors. The elation/loss of insight factor appears to capture 
mania as traditionally envisioned (e.g., elation, expansive 
mood) along with disconnect from reality (e.g., invinci-
bility, indestructibility). In contrast, the affrontive symp-
toms capture the irritable and ill-tempered ways in which 
mania can present, especially with older adults (Krauss 
Whitbourne 2000). This factor is positively correlated 
with each of the other three, including both depressive 
factors—and more strongly with cognitive and somatic 
factors of depression than elation/loss of insight.
The large, international sample of respondents recruited 
for this study is a definitive strength; follow-up data collec-
tion confirmed initial findings and demonstrated measure-
ment consistency over time. These findings support both 
the validity and reliability of the BD Sx over time. Although 
participants were drawn from all English-speaking coun-
tries, comparatively few persons with BD from minority 
communities were recruited. Further study is warranted 
with more representative samples and research is needed 
comparing BD Sx responses relative to clinical assessment 
of depression and hypo/manic mood episodes.
Ongoing BD research
For the BADAS Study, we have developed both am 
(morning) and pm (afternoon/evening) versions of our 
iOS app. Participants complete the BD Sx as well as sleep 
quality and medication adherence (am version) and 
any important events of the day (pm version). At enrol-
ment, participants specify windows of general availability 
and, by corollary, times of day when generally unavail-
able. They are randomly prompted twice daily within 
Table 2 BD Sx: list of  words that  describe feelings people 
have. After reading each, please indicate how  the word 
reflects how  you feel—right now, at this moment: 0 not 
at all, 1 a little, 2 a lot
Scoring key:
Cognitive symptoms = 1, 7, 11, 13, 17, 19
Somatic symptoms = 3, 9, 12, 15
Affrontive symptoms = 4, 5, 8, 18, 20
Elation/loss of insight = 2, 6, 10, 14, 16
1. miserable 0 1 2
2. talkative 0 1 2
3. tired 0 1 2
4. hostile 0 1 2
5. disgusted 0 1 2
6. impulsive 0 1 2
7. worthless 0 1 2
8. furious 0 1 2
9. sleepy 0 1 2
10. indestructible 0 1 2
11. insecure 0 1 2
12. fatigued 0 1 2
13. gloomy 0 1 2
14. invincible 0 1 2
15. exhausted 0 1 2
16. euphoric 0 1 2
17. lonely 0 1 2
18. suspicious 0 1 2
19. hopeless 0 1 2
20. argumentative 0 1 2
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30-minute windows and receive up to three prompts 
(initial, 20, and 25 min thereafter). If they respond after 
the first (or second) prompt, they do not hear the second 
(or third) prompt. Participants can also submit volun-
tary questionnaires at any point if something significant 
occurs that they wish to report.
EMS responses are time- and GPS-stamped so that we 
can determine if skipped questionnaires are missing at 
random or missing systematically (e.g., while manic only). 
Recent research indicates that smartphone sensors can pre-
dict BD symptomatology with considerable accuracy (Osm-
ani et  al. 2015). By measuring hypo/manic and depressive 
symptoms and symptom variability with the BD Sx, we can 
include this subjective information to further refine person-
specific algorithms to better identify predictors of mood 
episodes and factors associated with wellness with BD over 
time. Data collection for the BADAS Study is underway.
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